An already established antineoplastic drug could potentially serve as a treatment option for intrahepatic cholangiocarcinoma (CCA), according to a study recently published in Discover Oncology. “The results of our present study indicate that lenvatinib has excellent antitumor activity in ICC cells and can inhibit ICC proliferation through induction of Gadd45a-mediated cell cycle arrest,” the authors…
Laparoscopic hepatectomy (LH) for patients with intrahepatic cholangiocarcinoma (CCA) leads to better surgical outcomes with similar oncological and survival outcomes when compared to open hepatectomy (OH), according to a systematic review and meta-analysis published in the European Journal of Surgical Oncology. The meta-analysis found that patients with intrahepatic CCA who received LH had better surgical…
FF-10502-01 is well tolerated with manageable side effects, in patients with solid tumors, including cholangiocarcinoma, according to a new study published in the journal Cancer. The treatment also had limited hematologic toxicity. The study also found that in patients with cholangiocarcinoma who were heavily pretreated with gemcitabine, FF-10502-01 led to durable partial responses and disease…
Serum extracellular vesicles (EVs) appear to contain proteins that could serve as potential biomarkers and aid in the early diagnosis and prognosis of cholangiocarcinoma (CCA), according to a recently published study in the Journal of Hepatology. Although the incidence of CCA has risen significantly in recent decades, most patients have a poor prognosis, mainly because many…
The management, epidemiology, and clinical outcomes of cholangiocarcinoma in Africa were systematically reviewed and published in BMC Gastroenterology. There were only 11 studies from 4 African countries, which is not representative of the whole continent. “Our current review provides some foundational published work needed to guide future studies and support proposed research,” first author Akwi…
A team of researchers from China developed a nomogram to assess the risk of venous thromboembolism in patients undergoing surgery for distal cholangiocarcinoma. They published their research in the Asian Journal of Surgery. The rate of venous thromboembolism is high among patients undergoing distal cholangiocarcinoma surgery and is associated with adverse outcomes. Read more about…
Cytotoxic and noncytotoxic chemotherapy do not seem to be significantly different in terms of overall and progression-free survival, overall response rate, and disease control in patients with combined hepatocellular cholangiocarcinoma. This is according to a new study published in the journal ESMO Open. The authors also reported that “immunotherapy may be effective in a subset…
Percutaneous ablation leads to favorable intermediate to long-term disease control in patients with recurrent or unresectable intrahepatic cholangiocarcinoma (iCCA), according to a new study published in the Journal of Vascular and Interventional Radiology. To assess the outcome of image-guided ablation in recurrent or unresectable iCCA, a team of researchers, led by Paul B. Shyn, MD,…
Immunotherapies have become a novel therapy of choice for the treatment of primary liver cancers such as cholangiocarcinoma.
Small-duct intrahepatic cholangiocarcinoma (iCCA) appears to be more frequently associated with exposure to asbestos than large-duct iCCA, according to a pilot study published in Scientific Reports. This finding suggests that asbestos fibers might represent a parenchymal risk factor for iCCA. “This pilot study must be confirmed by further case-control studies or large independent cohorts,” the…
Please login or register first to view this content.
